Designer Glycopeptides for Cytotoxic T Cell-based Elimination of Carcinomas

Yanfei Xu, Sandra J. Gendler, Alessandra Franco

Research output: Contribution to journalArticlepeer-review

66 Scopus citations


Tumors express embryonic carbohydrate antigens called tumor-associated carbohydrate antigens (TACA). TACA-containing glycopeptides are appealing cytotoxic T cell (CTL)-based vaccines to prevent or treat cancer because the same sugar moieties are expressed in a variety of tumors, rendering a vaccination strategy applicable in a large population. Here we demonstrate that by using glycopeptides with high affinity for the major histocompatibility complex and glycosylated in a position corresponding to a critical T cell receptor (TcR) contact, it is possible to induce anti-TACA CTL in vivo. In the current study we show that designer glycopeptides containing the Thomsen-Freidenreich (TF) antigen (β-Gal-[1→3]-α -GalNAc-O-serine) are immunogenic in vivo and generate TF-specific CTL capable of recognizing a variety of tumor cells in vitro including a MUC1-expressing tumor. The fine specificity of the TF-specific CTL repertoire indicates that the TcR recognize the glycosylated amino acid residue together with TF in a conventional major histocompatibility complex class I-restricted fashion. These results have high potential for immunotherapy against a broad range of tumors.

Original languageEnglish (US)
Pages (from-to)707-716
Number of pages10
JournalJournal of Experimental Medicine
Issue number5
StatePublished - Mar 1 2004


  • CTL
  • Carcinomas
  • Glycopeptides
  • Immunotherapy
  • Tumor-associated carbohydrate antigens

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Designer Glycopeptides for Cytotoxic T Cell-based Elimination of Carcinomas'. Together they form a unique fingerprint.

Cite this